Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Expands Fibrosis Pipeline With Galecto Buy Option

This article was originally published in Start Up

Executive Summary

Three-year-old Galecto Biotech on November 3 secured funding and validation from Bristol-Myers Squibb Co. in an option-to-buy deal that could be worth up to $444 million. Galecto’s lead asset, an inhaled inhibitor of galectin-3 in development for idiopathic pulmonary fibrosis, has only just entered human testing. But IPF – and fibrosis more broadly – has become something of a hot-spot.



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts